Company Description
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel.
The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products.
It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
| Country | Israel |
| Founded | 1997 |
| IPO Date | Jan 23, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Dr. Alon Seri-Levy |
Contact Details
Address: 7 Golda Meir St., Weizmann Science Park Ness Ziona, L3 7403648 Israel | |
| Phone | 97289313433 |
| Website | sol-gel.com |
Stock Details
| Ticker Symbol | SLGL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001684693 |
| CUSIP Number | M8694L103 |
| ISIN Number | IL0011417206 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alon Seri-Levy | Co-Founder, Chief Executive Officer and Director |
| Gilad Mamlok | Chief Financial Officer |
| Dr. Itzik Yosef | Chief Operating Officer |
| Moshe Arkin | Executive Chairman of the Board |
| Prof. David Avnir | Co-Founder |
| Tamar Fishman Jutkowitz | Vice President and General Counsel |
| Dr. Karine Neimann | Vice President of Projects and Planning and Chief Chemist |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 15, 2024 | 6-K | Report of foreign issuer |
| May 28, 2024 | 6-K | Report of foreign issuer |
| May 20, 2024 | 424B3 | Prospectus |
| May 20, 2024 | 6-K | Report of foreign issuer |
| May 16, 2024 | 6-K | Report of foreign issuer |
| Apr 8, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 4, 2024 | 424B3 | Prospectus |
| Apr 1, 2024 | EFFECT | Notice of Effectiveness |
| Apr 1, 2024 | 6-K | Report of foreign issuer |
| Mar 20, 2024 | POS AM | Post-Effective amendments for registration statement |